Federation of Asian Biotech Associations (FABA)’s Post

There are countless medical conditions without effective therapeutic options. Equipped with advancements in #AI and #MachineLearning, this is all about to change.     On April 3, join our EVP, R&D, Alexandra Snyder, MD, for a webinar by Drug Discovery News and sponsored by Thermo Fisher Scientific.       Learn how we are revolutionizing the way we identify new drug targets, optimize drug design, and expedite the development process to address the most pressing unmet medical needs.     👉 Register now: https://lnkd.in/dhCiiBcS   #GenerativeBiology I #PatientFocusedDrugDevelopment  

Last month, Michael Chen, our CEO, participated in a thought-provoking panel at HLTH Europe titled "Thrills, Pills, & VC Bills: What Will it Take to Unleash Innovation in the World of Drug Development?". The panel explored the integration of advanced technologies like artificial intelligence, high-throughput screening, and computational modeling in drug development. These innovations are revolutionizing the identification of potential drug candidates and the prediction of their efficacy and safety profiles, bringing rapid innovation closer to reality.  🚀 Key takeaways from the panel include: ● The transformative role of AI in accelerating drug discovery and optimizing clinical trials. ● The impact of high-throughput screening in reducing initial testing times. ● The potential of computational models to streamline preclinical and clinical phases. The importance of technologies like eProtein Discovery for accelerating protein production, a critical step in drug development. Michael, along with Karen Madden (Merck Life Science), Geraldine O'Keeffe (EQT Partners), and Ignacio H. Medrano (SAVANA), emphasized the importance of collaboration and the need for increased investment to support innovative projects.  #HLTHEurope #proteinacess

As someone whose job it is to think about the translation of early-stage science to medicine, it's been really rewarding to help shape a multi-panel session that gets deep into the ways that is hard, and how to move forward. Join us in Nashville Sept. 9-11 to get in on the conversation! Breakthrough translational discoveries face critical bottlenecks that limit their path to value-driving drug development. Inefficiencies in translation range from poor disease models, to underdeveloped delivery technology, to mismatched expectations for what constitutes validation. At #BioCenturyGrandRounds, the Translational Bottlenecks Session will unpack the strategies for overcoming these roadblocks: ➤ From causal biology to preclinical validation: What makes the grade in 2024? ➤ The human-first era is here: Is there still value in new animal models? ➤ Delivery on demand: Still the elephant in the room Download the conference brochure to view the full agenda: https://loom.ly/TGB3Mmk Register: https://loom.ly/xUy6IGo #translationalbottlenecks #drugdevelopment #translationalscience #biotech #biopharma

How does the only Global Integrated Analytical Biorepository facilitate translational research? Translational research is an essential bridge between fundamental research findings and clinical application, requiring meticulous management of complex, long-term projects with the highest research standards. Read our latest white paper to learn more about how Sampled is here to support throughout the drug development pipeline: https://lnkd.in/e7V5ifnF #TranslationalResearch #GIAB #TeamSampled

"Unifying and illuminating clinical, biomarker, and sample data." QuartzBio, part of Precision for Medicine specializes in integrating and managing clinical, biomarker, and sample data to enhance visibility and collaboration across biomedical research and development projects. Their platform facilitates the harmonization of siloed data, promoting efficiency in drug development processes. Learn more at https://www.quartz.bio/ #Bio #DataManagement #SoHCSpotlights

🧬 Unlocking the Potential of Small Molecules in Medicine 🧬 Why are small molecules a cornerstone in therapeutic development? Join Dr. Kishore V Renduchintala, Executive VP and Head of Discovery Sciences at LAXAI Life Sciences, at our Drug Discovery & Development Workshop as he unpacks the power and potential of small molecules to treat complex diseases. From design to synthesis, learn how advances in medicinal chemistry are leading to more effective and safer drug therapies. Kishore's session will cover: - Latest techniques in lead optimization - Challenges in drug design for targeted therapies - Case studies on breakthrough small molecule drugs 🌐 Dr. Renduchintala brings over two decades of experience and will share insights into how small molecules are designed, optimized, and developed into life-saving treatments. 📅 Event Date: 3-16 August, 2024 👉 Register Here: https://lnkd.in/ekGgYQkZ #MedicinalChemistry #DrugDesign #DDD2024

Fascinating experience attending the #interphex conference in Tokyo today, the biggest #Pharma event of the year! Walking the massive exhibition halls added a serious step count. One striking trend I noticed as a newbie is the focus on #celltherapy and #genetherapy technologies and solutions by many companies. This signifies the ongoing shift to #precisionmedicine and the exciting possibilities in healthcare future. 💉💊⚕️🧬🎌 Looking forward to further discussions with industry leaders on the impact of genomics in this trend. #NGS deployment in quality control protocols is already in progress. One crucial question I aim to explore more is, “how can we enhance your workflow to provide a more comprehensive answer, enabling you to proceed with confidence to the next step?” 🏭🧫🧪🧑🔬 Excited to delve deeper into this conversation. What other questions do you suggest I should be asking?

In collaboration with pharmaceutical group company OpREMS, LLC., a research team at North Dakota State University has received an $296k award from the The National Institutes of Health Small Business Technology Transfer (#STTR) program to conduct research for NDSU's #Opioid and #Naloxone Education ONE Program. The research will develop and refine a digital platform incorporating current ONE Program tools. Artificial intelligence will be utilized to analyze data to recognize the screening tools that have the most significant clinical impact. NDSU researchers Jayme Steig, Jeremy Straub, Elizabeth Skoy, and Lisa Nagel will conduct the research in collaboration with Nick Ferrarese. STTR aims to foster technology transfer through cooperative R&D between small businesses and research institutions. STTR and the Small Business Innovation Research (SBIR) program collectively form the NIH Small Business Program which is also known as America’s Seed Fund. NDSU Department of Pharmacy Practice CAP Center - Center for Collaboration and Advancement in Pharmacy #AI #NaloxoneEducation #technologytransfer #STTR #AmericasSeedFund https://lnkd.in/gJAE7V38

Today I am proud to announce Lifebit’s data catalog has reached over 100M patients’ data, covering health and multi-omic data across +200 conditions, from >30 of our valued global data partners. This represents the world’s most diverse clinical-genomics data resource, and has the potential to be truly transformative for our pharma partners to advance precision medicine and generate discoveries that save lives. With data serving as the new productivity driver for the pharmaceutical industry at Lifebit our teams are working tirelessly to revolutionize healthcare by providing researchers with unparalleled access to diverse datasets crucial for understanding diseases and developing life-saving treatments. This achievement could not have been possible without the dedication of our team and our collaborations with leading healthcare providers, research institutions and population genomics initiatives across the globe. Together, we are paving the way for a future where access to biomedical data is never again an obstacle to curing diseases. Read our press release for more details: https://bit.ly/3uPLMu7 #PrecisionMedicine #Biotech #DataInnovation #Lifebit #datasaveslives

How can we refine and de-risk drug development process and start using reliable sources in clinical trials, exponentially increasing the efficiency and effectiveness of research? Yesterday, we highlighted the challenges that the #clinicalresearch environment is currently facing, but these limitations can be overcome through innovation. ELEM virtualizes medical trials and patients using advanced mathematical models, enabling the prediction of treatment outcomes in real patient conditions. Currently, medical devices and drugs are tested without taking into account the variation and diversity of individuals… but with supercomputers, there is no limit to either the number of tests that can be done or the number of variables that can be considered, thus making the drug suitable for anyone and being able to take into account age, gender, ethnic groups and so on. ELEM is the future of medicine. Now! If you are interested in discovering our contribution to revolutionizing the clinical trial environment, send us a DM or follow this link: https://www.elem.bio. #medtech #clinicaltrials #animaltesting #EUeic